Back to Newsroom
Back to Newsroom

CLASS ACTION UPDATE for BIIB, BABA and NAK: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders

Monday, 11 January 2021 12:25 PM

Levi & Korsinsky, LLP

Topic:
Lawsuits

NEW YORK, NY / ACCESSWIRE / January 11, 2021 / Levi & Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies. Shareholders interested in serving as lead plaintiff have until the deadlines listed to petition the court. Further details about the cases can be found at the links provided. There is no cost or obligation to you.

BIIB Shareholders Click Here: https://www.zlk.com/pslra-1/biogen-inc-loss-submission-form?prid=12070&wire=1
BABA Shareholders Click Here: https://www.zlk.com/pslra-1/alibaba-group-holding-limited-loss-submission-form?prid=12070&wire=1
NAK Shareholders Click Here: https://www.zlk.com/pslra-1/northern-dynasty-minerals-ltd-loss-submission-form?prid=12070&wire=1

* ADDITIONAL INFORMATION BELOW *

Levi & Korsinsky, LLP, Monday, January 11, 2021, Press release picture

Biogen Inc. (NASDAQ:BIIB)

BIIB Lawsuit on behalf of: investors who purchased October 22, 2019 - November 6, 2019
Lead Plaintiff Deadline : January 12, 2021
TO LEARN MORE, VISIT: https://www.zlk.com/pslra-1/biogen-inc-loss-submission-form?prid=12070&wire=1

According to the filed complaint, during the class period, Biogen Inc. made materially false and/or misleading statements and/or failed to disclose that: (1) the larger dataset did not provide necessary data regarding aducanumab's effectiveness; (2) the EMERGE study did not and would not provide necessary data regarding the effectiveness of aducanumab, Biogen's investigational human monoclonal antibody studied for the treatment of early Alzheimer's disease; (3) the PRIME study did not and would not provide necessary data regarding aducanumab's effectiveness; (4) the data provided by the Company to the U.S. Food and Drug Administration's Peripheral and Central Nervous System Drugs Advisory Committee did not support finding efficacy of aducanumab; and (5) as a result, Defendants' statements about its business, operations, and prospects, were materially false and misleading and/or lacked a reasonable basis at all relevant times.

Alibaba Group Holding Limited (NYSE:BABA)

BABA Lawsuit on behalf of: investors who purchased July 9, 2020 - December 23, 2020
Lead Plaintiff Deadline : January 12, 2021
TO LEARN MORE, VISIT: https://www.zlk.com/pslra-1/alibaba-group-holding-limited-loss-submission-form?prid=12070&wire=1

According to the filed complaint, during the class period, Alibaba Group Holding Limited made materially false and/or misleading statements and/or failed to disclose that: (1) Ant Small and Micro Financial Services Group Co., Ltd. ("Ant Group"), a financial technology company in which Alibaba owns a 33% equity interest, did not meet listing qualifications or disclosure requirements for certain material matters; (2) certain impending changes in the Fintech regulatory environment would impact Ant Group's business; (3) as a result of the foregoing, Ant Group's initial public offering was reasonably likely to be suspended; and (4) as a result of the foregoing, Defendants' positive statements about the Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis.

Northern Dynasty Minerals Ltd. (NYSE:NAK)

NAK Lawsuit on behalf of: investors who purchased December 21, 2017 - November 25, 2020
Lead Plaintiff Deadline : February 2, 2021
TO LEARN MORE, VISIT: https://www.zlk.com/pslra-1/northern-dynasty-minerals-ltd-loss-submission-form?prid=12070&wire=1

According to the filed complaint, during the class period, Northern Dynasty Minerals Ltd. made materially false and/or misleading statements and/or failed to disclose that: (1) the Company's Pebble Project was contrary to Clean Water Act guidelines and to the public interest; (2) the Company planned that the Pebble Project would be larger in duration and scope than conveyed to the public; (3) as a result, the Company's permit applications for the Pebble Project would be denied by the U.S. Army Corps of Engineers; and (4) as a result, Defendants' public statements were materially false and/or misleading at all relevant times.

You have until the lead plaintiff deadlines to request that the court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.

Levi & Korsinsky is a nationally recognized firm with offices in New York, California, Connecticut, and Washington D.C. The firm's attorneys have extensive expertise and experience representing investors in securities litigation and have recovered hundreds of millions of dollars for aggrieved shareholders. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:

Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
55 Broadway, 10th Floor
New York, NY 10006
[email protected]
Tel: (212) 363-7500
Fax: (212) 363-7171
www.zlk.com

SOURCE: Levi & Korsinsky, LLP

Topic:
Lawsuits
Back to newsroom
Back to Newsroom
Share by: